Kodiak Sciences KOD 深 沪
等待开盘 08-10 09:30:00 美东时间
45.37
-0.030
-0.07%
华盛通- 最 高46.87
- 今 开46.12
- 成交量 46.35万股
- 最 低 39.38
- 昨 收 45.40
- 总市值 235.71万
- 52周最高 47.8417
- 市盈率 静 --
- 换手率 892.21%
- 52周最低 8.29
- 委 比 17.79%
- 总股本 5.20万
- 历史最高 171.21
- 量 比 0.85
- 振 幅 16.50%
- 历史最低 1.10
- 每 手 1
- 风险率 10.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday
Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainers include Kodiak Sciences Inc and Precigen Inc.
03-26 22:04
Dow Falls 250 Points; US Initial Jobless Claims Rise
Dow and NASDAQ down over 0.5%, S&P 500 down 0.82%. Energy shares up, communication services down. U.S. initial jobless claims in line with estimates.
03-26 21:47
【山证汽车】汽车智能驾驶专题：智驾已是“必答题”，低阶配置平权与高阶功能落地共振
投资要点 近年来，智能已经是各家汽车企业的“必答题”，无论新能源、燃油车智能功能渗透率正在快速提升。特别是智驾平权趋势下，行业有望迎来加速增长。全球智能汽车销量...
2025-10-22 09:35
2025 KOD全球街舞大赛新闻发布会在京举行，国际顶尖街舞盛会全面启幕
来源：北青网 6月17日，伴随震撼的节奏和动感的舞步，2025 KOD全球街舞大赛新闻发布会在国家网球中心钻石球场新闻发布厅隆重举行。 发布会现场，朝...
2025-06-18 13:44
Kodiak Sciences Completes Enrollment In Second Registrational Trial Of Tarcocimab In Patients With Diabetic Retinopathy; Topline Clinical Data Of The Confirmatory Registrational Study GLOW2 Expected In Q1 2026
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026.GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical
2025-03-11 04:40
HC Wainwright & Co. Initiates Coverage On Kodiak Sciences with Neutral Rating, Announces Price Target of $3
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Kodiak Sciences (NASDAQ:KOD) with a Neutral rating and announces Price Target of $3.
2024-09-05 18:50
